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344 Abstractslanding zone, of whom 3 with concomitant extra-anatomic
debranching of the supra-aortic vessels. Technical success was
achieved in 100%. The 30-day mortality rate was 16.7% (n ¼ 4).
Two patients had paraplegia. Neither stroke nor renal insufﬁciency
requiring new dialysis occurred. During a mean follow-up of 28
months, another death in relation with dissection occurred and 8
patients (33%) required reintervention. All reintervention were
managed by endovascular means. At last follow up CT-scan, 8
patients (33%) had complete remodeling of the aortic wall.
Conclusion: This study conﬁrms the feasibility of TEVAR for R-BAD
and its lower perioperative morbidity and mortality rate compared
to open surgery, reducing by more than 2 third the 30-day mor-
tality. However the rate of reintervention is high and a long term
follow up is mandatory.
Dipeptidyl Peptidase-4 Inhibitor Alogliptin Prevents Further
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Introduction: Dipeptidyl peptidase-4 inhibitor alogliptin has been
proved to prevent abdominal aortic aneurysm (AAA) formation.
However, the mechanism of alogliptin on aneurysm development
has not been sufﬁciently investigated. The objective of this study
was to determine how alogliptin prevents further dilation of AAA
development mimicking clinical setting.
Methods: The AAA model induced with intraluminal elastase and
extraluminal calcium chloride was created in 42 rats. Forty-two rats
were divided 3 groups: a low-dose of alogliptin group (Group LD; 1
mg/kg/day), a high-dose group (Group HD; 3 mg/kg/day), and a
control group (Group C, water). Alogliptin administration by gastric
gavage once per daywas started on 7 days after aneurysm formation
(Dilatation ratio: 158.9 7.7%). On day 14, reactive oxygen species
(ROS) expression and the oxidation product of DNA 8-
hydroxydeoxyguanosine (8-OHdG) was measured. As ROS have
been reported to activate ERK pathway which is important modu-
lator of MMPs and inﬂammatory cytokines, MMP expression and
inﬂammatory response were also analyzed along with ERK evalua-
tion. Histopathological examination was performed on day 28, and
the AAA dilatation ratio was calculated to evaluate alogliptin pro-
tective effect.
Results: On day 14, ROS expression and 8-OHdG positive cells in
aneurysm walls were decreased by alogliptin treatment (ROS
expression: 4.4  0.6 in Group C, 3.2  0.1 in Group LD, and 2.7 
0.3 in Group HD, p < 0.001; 8-OHdG-positive cells: 167.4  6.9
cells in Group C, 102.7  19.9 cells in Group LD, and 64.7  2.7
cells in Group HD, p < 0.001). Western blot analysis showed
decrease ERK levels in treatment groups compared with in control
group. The treatment signiﬁcantly reduced mRNA expression of
MMPs, TNF-a and MCP-1 in aneurysm walls. Immunohistochemical
staining for CD68 demonstrated the decrease of macrophage
inﬁltration in aneurysm wall with treatment groups. On day 28, the
aortic wall in groups LD and HD were less dilated, and had higher
elastin content than those in Group C (Dilatation ratio: 199.2 
10.8% in Group C, 170.0  4.4% in Group LD, and 155.1  2.3% in
Group HD, p < 0.001).
Conclusion: Alogliptin treatment starting after aneurysm forma-
tion inhibits further dilation in rat model through anti-oxidant and
anti-inﬂammatory effect. Inhibition of ERK activation by reducing
oxidative stress prevented inﬂammatory response and matrix
degeneration, resulting in prevention of the aortic dilatation.High Frequency of AAA in the North of Sweden Not Explained by
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Introduction: The frequency of Abdominal Aortic Aneurysm (AAA)
is higher in the north region of Sweden compared to the south
with a 38% higher incidence for AAA in men. Smoking is less
common in the north and can subsequently not be responsible for
the increased risk. A strong hereditary trait has been suggested as
an explanation to the regional differences in disease pattern.
Organized screening for AAA in siblings is currently not arranged in
either region. Our aim was to investigate if siblings to AAA-patients
in the north part of Sweden have a higher prevalence of AAA
compared to siblings in the Stockholm region (mid).
Methods: All patients treated for AAA between Jan 2008eAug
2012 at two hospitals covering a large county of the north were
screened for siblings (n ¼ 483). The living siblings residing in the
north were offered an ultrasound scan of the abdominal aorta
preceded by a structured telephone interview regarding health
and medications. Ultrasound was performed by one validated
examiner using both LELE and OTO-technique. The result of the
ultrasound-examination was compared to the previously published
results of the prevalence of AAA in siblings in Stockholm (mid
Sweden).
Results: 379 siblings were included of which 8 had undergone
aortic repair and 8 had a known AAA under surveillance. 363 were
screened with ultrasound. The prevalence of AAA in all siblings was
34/379 (10%, brothers 14%, sisters 6%). There was no difference in
the prevalence of AAA in siblings from north compared to mid
region (p ¼ 0.75). Smoking was as common in both regions among
siblings with AAA.
Conclusion: Our data do not support a strong hereditary trait for
AAA in the north part of Sweden compared to other regions. The
results reinforce the importance of developing structured
screening protocols for ﬁrst degree relatives to AAA patients, since
the prevalence in siblings is strikingly high as compared to the
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Introduction: Ipsilateral, single segment great saphenous vein
(GSV) remains the optimal conduit for below knee bypass to treat
critical limb ischemia. There is a need to better deﬁne the beneﬁt
of alternative autologous vein (AAV) segments over contemporary
prosthetic conduits in patients in whom GSV is not available.
Methods: Patients who underwent bypass to below-knee targets
for chronic arterial occlusive disease between 2007e2011 were
retrospectively reviewed and categorized in three groups: GSV;
AAV (small saphenous veins, arm veins or spliced vein segments);
Prosthetic. The primary outcome was graft patency (primary,
assisted primary, secondary). Secondary outcome was limb
salvage. Cox regression models were used to assess the effect of
baseline predictors. Results were considered statistically signiﬁcant
when p-value was <0.05.
